Autopsy report · NCT04371926

Prophylactic Benefit of Hydroxychloroquine in COVID-19 Cases With Mild to Moderate Symptoms and in Healthcare Workers With High Exposure Risk

“Concerned about the adverse effects of HCQ”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Na

Sponsor

Texas Cardiac Arrhythmia Research Foundation

Sponsor type

University, hospital or other

Conditions

COVID-19

Interventions

Hydroxychloroquine Sulfate

Participants

0

Trials that died the same way

• Hydroxychloroquine for the Treatment of Patients With Mild to Moderate COVID-19 to Prevent Progression to Severe Infection or Death
  “Trial not started due to accumulating evidence against HCQ for COVID” (61% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.